Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of CAPRELSA is substantial. |
Clinical Added Value
| minor |
The transparency Commission considers that CAPRELSA provides a minor improvement in the actual benefit (IAB level IV) in the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. |
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
qVce7vE5UJBps0dh
